These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 20357493

  • 1. Evaluation of a 6-year highly active antiretroviral therapy in Chinese HIV-1-infected patients.
    Zhou HY, Zheng YH, He Y, Chen Z, Liu M, Yin W, Liu C.
    Intervirology; 2010; 53(4):240-6. PubMed ID: 20357493
    [Abstract] [Full Text] [Related]

  • 2. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H, Zheng YH, Shen Z, Liu M, Liu C, He Y, Chen J, Ou QY, Huang ZL.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 13; 87(42):2973-6. PubMed ID: 18261327
    [Abstract] [Full Text] [Related]

  • 3. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
    Reliquet V, Allavena C, François-Brunet C, Perré P, Bellein V, Garré M, May T, Souala F, Besnier JM, Raffi F.
    HIV Med; 2006 Oct 13; 7(7):431-6. PubMed ID: 16925728
    [Abstract] [Full Text] [Related]

  • 4. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA, López JC, Santos I, Estrada V, Castilla V, Sanz J, Sanz J, Molina JP, Fernández Guerrero M, Górgolas M.
    HIV Med; 2005 Sep 13; 6(5):353-9. PubMed ID: 16156884
    [Abstract] [Full Text] [Related]

  • 5. [Therapeutic effect and safety evaluation on 6-year highly active antiretroviral therapy for Chinese HIV-1 infected patients].
    Zhou H, Zheng Y, He Y, Gong G, Chen Z, Liu M, Yin W, Liu C.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Aug 13; 34(8):731-7. PubMed ID: 19734579
    [Abstract] [Full Text] [Related]

  • 6. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
    Liu ZY, Guo FP, Han Y, Qiu ZF, Zuo LY, Li YL, Li TS.
    Chin Med J (Engl); 2009 Oct 20; 122(20):2497-502. PubMed ID: 20079166
    [Abstract] [Full Text] [Related]

  • 7. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load.
    Gil P, de Górgolas M, Estrada V, Arranz A, Rivas P, Yera C, García R, Granizo JJ, Fernández-Guerrero M.
    Clin Infect Dis; 2004 Oct 01; 39(7):1024-9. PubMed ID: 15472856
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Ribera E, Rodríguez-Pardo D, Rubio M, Soler A, Pedrol E, Blanco JL, González A, Crespo M, Falcó V, Ocaña I, Deig E, Miró JM, Pahissa A.
    Antivir Ther; 2005 Oct 01; 10(5):605-14. PubMed ID: 16152754
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.
    Song R, Jelagat J, Dzombo D, Mwalimu M, Mandaliya K, Shikely K, Essajee S.
    Pediatrics; 2007 Oct 01; 120(4):e856-61. PubMed ID: 17846147
    [Abstract] [Full Text] [Related]

  • 10. Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study.
    Manosuthi W, Chumpathat N, Chaovavanich A, Sungkanuparph S.
    BMC Infect Dis; 2005 Aug 24; 5():67. PubMed ID: 16120209
    [Abstract] [Full Text] [Related]

  • 11. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
    Plana M, Ferrer E, Martínez C, Podzamczer D, García F, Maleno MJ, Barceló JJ, García A, Barberá MJ, Lacarcel M, Miró JM, Gallart T, Gatell JM.
    Antivir Ther; 2004 Apr 24; 9(2):197-204. PubMed ID: 15134181
    [Abstract] [Full Text] [Related]

  • 12. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
    Achenbach CJ, Till M, Palella FJ, Knoll MD, Terp SM, Kalnins AU, Murphy RL.
    HIV Med; 2005 Jan 24; 6(1):7-12. PubMed ID: 15670246
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P, ANRS 127 Study Group.
    J Antimicrob Chemother; 2009 Jul 24; 64(1):118-25. PubMed ID: 19420019
    [Abstract] [Full Text] [Related]

  • 14. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
    Ruiz L, Paredes R, Gómez G, Romeu J, Domingo P, Pérez-Alvarez N, Tambussi G, Llibre JM, Martínez-Picado J, Vidal F, Fumaz CR, Clotet B, TIBET Study Group.
    AIDS; 2007 Jan 11; 21(2):169-78. PubMed ID: 17197807
    [Abstract] [Full Text] [Related]

  • 15. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD, Keruly JC.
    Clin Infect Dis; 2007 Feb 01; 44(3):441-6. PubMed ID: 17205456
    [Abstract] [Full Text] [Related]

  • 16. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N'dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F.
    Clin Infect Dis; 2008 Feb 15; 46(4):611-21. PubMed ID: 18197758
    [Abstract] [Full Text] [Related]

  • 17. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.
    Tin EE, Bowonwatanuwong C, Desakorn V, Wilairatana P, Krudsood S, Pitisuttithum P.
    Southeast Asian J Trop Med Public Health; 2005 Mar 15; 36(2):362-9. PubMed ID: 15916042
    [Abstract] [Full Text] [Related]

  • 18. Virologic outcomes of first-line HAART and associated factors among Chinese patients with HIV in three sentinel antiretroviral treatment sites.
    Ruan Y, Xing H, Wang X, Tang H, Wang Z, Liu H, Su B, Wu J, Li H, Liao L, Li J, Wu JW, Shao Y.
    Trop Med Int Health; 2010 Nov 15; 15(11):1357-63. PubMed ID: 20868414
    [Abstract] [Full Text] [Related]

  • 19. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
    Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, Luna E, González A, Pedrol E, Lozano L, Ocaña I, Llibre JM, Casiró A, Aranda M, Barrufet P, Martínez-Lacasa J, Miró JM, Badía X, Casado A, Lupo S, Cahn P, Maños M, Estela J.
    Antivir Ther; 2002 Jun 15; 7(2):81-90. PubMed ID: 12212928
    [Abstract] [Full Text] [Related]

  • 20. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
    Negredo E, Miró O, Rodríguez-Santiago B, Garrabou G, Estany C, Masabeu A, Force L, Barrufet P, Cucurull J, Domingo P, Alonso-Villaverde C, Bonjoch A, Morén C, Pérez-Alvarez N, Clotet B, MULTINEKA Study Group.
    Clin Infect Dis; 2009 Sep 15; 49(6):892-900. PubMed ID: 19663689
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.